Norway (as an EFTA State) has implemented Regulation (EC) No 726/2004 of the European Parliament and of the Council, EEA agreement annex II, chapter XIII.
The EFTA States shall participate in the work of the European Medicine Agency as set up by Regulation (EC) 726/2004. When a decision on approval of medicinal products are taken according to the Committee procedures laid down in  Regulation (EC) No 726/2004, The EFTA States shall simultaneously and within 30 days of the Committee Decision, take corresponding decisions on the basis of the relevant acts. The EEA Joint Committee shall be informed and shall periodically publish lists of such decisions in the EEA Supplement to the Official Journal. 
According to the procedures for authorisation of medicinal products for human use or a veterinary medicinal product containing or consisting of genetically modified organisms, the opinion of the Committee shall respect the environmental requirement laid down by Directive 2001/18/EC.

The Advance Informed Agreement procedure of the protocol is implemented in the Norwegian legislation through the Gene Technology Act and its regulations.
According to the Act, a company intending to release a GMO into the environment in Norway must first obtain an approval, unless the GMO in question has been approved for placing on the market by the Directive in the EU. As a consequence of the EEA Agreement (also described under question 75), Norway takes part in the approval procedure of GMO in the EU on the same basis as the EU Member States, with the exception of voting procedures. A GMO which has been approved by the Directive for placing on the market in the EU is also approved for that purpose in Norway, unless the competent authority in Norway considers it to constitute a risk to human health or the environment or otherwise contravene the Gene Technology Act's assessment criteria sustainability, ethics and social utility and therefore has decided to restrict or prohibit its placing on the market in Norway. This only applies to directive 2001/18/EC and not to the regulation 1829/2003/EC as the latter regulation has not been implemented in Norway. This only applies to directive 2001/18/EC and not to the regulation 1829/2003/EC as the latter regulation has not been implemented in Norway.
The application is subject to public consultation and consideration by the Scientific Committee on Food Safety, the Food Safety Authority, the Norwegian Biotechnology Advisory Board, the Norwegian Environment Agency and the Ministry of Climate and Environment. Approval may be conditional and granted for a limited time. The conditions of the approval may be altered and the approval may be revoked if certain conditions are met.
In contrast to applications for marketing of LMOs, applications for experimental release into the environment is subject to a national procedure
In regard to question 44, reporting on approving the import with conditions, we recognize the requirement of GMO-labelling as a condition. With regard to requesting additional information Norway has, from 2008, on a routine basis requested additional information according to the purpose of Norwegian gene technology Act, as set out in its section 1, is to ensure that the production and use of genetically modified organisms take place in an ethically justifiable and socially acceptable manner, in accordance with the principle of sustainable development.

The Norwegian legislative framework addresses LMOs-FFP, and does not lay down other procedures for LMOs-FFP than for LMOs.

Section 8 of The Norwegian Gene Technology Act establishes that the conditions attached to an approval may be altered, and if necessary the approval may be withdrawn if: a) the risk to health or the environment posed by the use in question proves to be greater than was foreseen when the use was approved, or  b) new technology makes it possible to reduce the risk of adverse effects on health or the environment, or c) contravene the Gene Technology Act's assessment criteria sustainability, ethics and social utility, or d) this otherwise follows from the rules for reversing decisions that are currently in force.

Norway has not applied the simplified procedure to LMOs for intentional introduction to the environment.
Norway has implemented Article 13a through national regulations relating to the labelling, transport, import and export of genetically modified organisms of 2 September 2005. The transport and import of genetically modified organisms may take place without special approval when the requirements in these regulations regarding labelling and packaging are fulfilled. Transport of genetically modified organisms which is covered by and fulfils the requirements in or is approved pursuant to rules applying to the transport of dangerous goods may take place without special approval. However, approval is required for the transport and import of the following genetically modified organisms:

- Genetically modified microorganisms where the activity is classified in risk classes 3 and 4.
- Volume of culture exceeding 10 litres of genetically modified microorganisms where the activity is classified in risk class 2.
- Live animals and plants used as host organisms for genetically modified microorganisms.
- Transport where it is not possible to satisfy the requirements in these regulations regarding packaging and labelling.
- All genetically modified animals, with the exception of
1. traditional livestock that have no wild relatives in Norwegian fauna with which they can interbreed,
2. laboratory animals, e.g. mice, rats, hamsters intended for use in laboratories approved for contained use of genetically modified organisms,
3. embryos, eggs, semen, cell and tissue cultures of animal cells 
These imports are not subject to reporting, and the number of LMOs the simplified procedure has been applied to is not known, but is assumed to be higher than five.

The Agreement on the European Economic Area, which entered into force on 1 January 1994, brings together the 27 EU Member States and the three EEA EFTA States - Iceland, Liechtenstein and Norway - in a single market, referred to as the "Internal Market". The EEA Agreement provides for the inclusion of EU legislation covering the four freedoms - the free movement of goods, services, persons and capital - throughout the 30 EEA States. In addition, the Agreement covers cooperation in other important areas such as research and development, education, social policy, the environment, consumer protection, tourism and culture, collectively known as "flanking and horizontal" policies.

As a consequence of the EEA Agreement, Norway takes part in the approval procedure for LMOs in the EC on the same basis as the EU Member States, with the exception of voting procedures. A LMO which has been approved for placing on the market for direct use for food, feed or for processing in the EU by Directive 2001/18/EC is also approved for those purposes in Norway, unless the competent authority in Norway considers it to constitute a risk to human health or the environment or otherwise contravene the Gene Technology Act and therefore has decided to restrict or prohibit its placing on the market in Norway.

Please see Q75

In our regulation this is required, however, as only genetically modified carnation as cut flowers has been approved it has not been relevant.

Before an LMO may enter the Norwegian market, an extensive risk assessment is conducted. The competent authorities ask the Norwegian Scientific Committee for food safety (VKM) to conduct a risk assessment. This means that the scientific assessment of environmental risks is separated from the risk handling, and that the whole process shall be carried out in an open and transparent way. Through competent authorities and advisory bodies, such as VKM, Norway takes active part not only in the risk assessments conducted by the EU, but also in the development of guidelines for the risk assessment of LMOs. 
Regulations relating to impact assessment pursuant to the Gene Technology Act provide a basic guideline on how to conduct risk assessments prior to taking decisions regarding LMOs. In addition, as stated as response to question 75, Norway participates in the EU approval process for LMOs, and The European Food Safety Authority (EFSA) provides more detailed guidelines on how to perform risk assessments of LMOs.
The environmental risk assessment should be conducted with a view to identify whether there is a need for risk management,  and if so, the most appropriate methods must be used. If new information on LMO and its effects on human health or the environment becomes available, the environmental risk assessment may need to be readdressed in order to:
- determine whether the risk has changed;
- determine whether there is a need for amending the risk management accordingly

For more information, please see Q191.
With regard to Q102-104; we have had no incidents of unintentional movements from Norway and thus we recognise these questions as not applicable

The Norwegian legislative framework addresses Article 18 of the protocol through inter alia Regulations relating to the labelling, transport, import and export of genetically modified organisms. The object of these Regulations is to simplify the transport and import of genetically modified organisms, fulfil Norway's obligations under the Cartagena Protocol relating to genetically modified organisms, ensure consumer choice and prevent adverse effects of genetically modified organisms.
Section 19. of the Regulations regarding labelling of products consisting of or containing genetically modified organisms establishes that such products shall be labelled in Norwegian and/or English with the words "Contains genetically modified organisms" alternatively "Contains genetically modified (name of organism(s))". On packaged products, the information shall be given on a label on each packaged unit. For other products, the information shall be given in an accompanying document or notice.

With regard to question 126n; as a consequence of the EEA agreement and implementation of Directive 2001/18/EC in Norway (also described in Q46 and Q75), GMOs approved by this Directive in EU are also legal to place on the marked in Norway, unless Norway decides to restrict or prohibit its placing on the marked according to the Norwegian gene technology act. However, we do not recognize a ban after an approval in EU as a change of a decisions.
With regard to Q126f, g, m, o and p: the correct answer would be not applicable.

The competent Norwegian authorities and relevant agencies have established biosafety websites. However, there is no central biosafety website.
According to the Norwegian Gene Technology Act, public consultations are mandatory for all applications for marketing of LMOs in Norway. Public awareness and participation is facilitated.
The Norwegian Biotechnology Advisory Board provides relevant information to the public through publications, seminars and workshops.

Regulations relating to the labelling, transport, import and export of genetically modified organisms do not require approval for transport and import of certain LMOs, such as laboratory animals intended for use in laboratories approved for contained use of genetically modified organisms and genetically modified microorganisms where the activity is classified in risk classes below 3 (cultures up to 1 litre). Imports and exports of such LMOs for research purposes to and from Non-Parties have taken place during the reporting period  

Pursuant to Sections 17, 18, 20, 21, 23, 24 and 25 of the Gene Technology Act, several measures can be used to prevent and penalize transboundary movements of GMO carried out in contravention of  the Norwegian legal framework on GMO, including supervision (Section 17), right of inspection (Section 18), order to cease activity (Section 20), duty to prevent and limit damage (Section 21), compensation (Section 23), coercive fine (Section 24) and penalties (Section 25).
Norwegian Environment Agency and the Norwegian Food Safety Authority perform supervision over the implementation of the Gene Technology Act. Each Year the Norwegian Food Safety Authority takes 100-150 samples of products consisting of, containing or produced from soy beans, maize, rape seeds, rice and papaya in their annually based monitoring and surveillance program 'Monitoring of genetically modified material'. The samples are taken from shipments, production sites and shops and are analysed for GMO, and documentation controls are performed.
So far the sampling and testing have in most cases revealed low levels (mostly below 0.9 %) of unintentional or technically unavoidable GMO presence in conventional soybeans, maize, rape seeds and rice. The papaya products were processed and, hence not considered LMO. However, one sample of maize from Argentina contained the illegal event Bt 176.
Due to the low level presence of GMO, documentation provided by the responsible persons/companies on the measures taken to avoid such GMO presence, the fact that the GMO present have been authorized in the European Union and an assessments of environmental and health risks related to the presence, it has been concluded that the presence did not contravene the Gene Technology Act.
However, during the current reporting period we have had one incidence of illegal genetically modified Zebra fish, as notified at BCH.
For emergency measures regarding specific non-authorised LMOs, please refer to the EU report.

The purpose of the Gene Technology Act is inter alia to ensure that the production and use of genetically modified organisms take place in an ethically justifiable and socially acceptable manner, in accordance with the principle of sustainable development and without adverse effects on health and the environment. Hence, socioeconomic considerations is a central part of the Norwegian impact assessment prior to the marketing of LMOs and LMOs-FFP.
The assessment of sustainability issues (ecological, economical and social) is to be performed on a global scale. This implies that considerations should  also focus on the country producing the LMO in question.
The assessment of the LMOs benefit to society is primarily focused on effects in Norway, such as whether the LMO helps solving a social problem, create employment opportunities or tend to create problems for existing production that in otherwise should be maintained.
Under the provisions of the Gene Technology Act, The Norwegian Biotechnology Advisory Board has a role in the assessments of LMOs. The main tasks of the Norwegian Biotechnology Advisory Board is to evaluate the social and ethical consequences of modern biotechnology and to discuss usage which promotes sustainable development.  
Norway is a member of the AHTEG on Socio-economic considerations and participates actively in the current activities under the Protocol aiming at exchanging information on socio-economic impacts of LMOs and working towards developing guidance.